Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
Sign Up to like & getrecommendations! Published in 2024 at "Nature Medicine"
DOI: 10.1038/s41591-024-03050-2
Abstract: CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) and is considered the best standard of care (SOC). To improve current… read more here.
Keywords: multiple myeloma; lenalidomide dexamethasone; isa vrd; negativity ... See more keywords
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-200135
Abstract: Introduction The anti-CD38 antibody isatuximab (Isa) mediates anti-myeloma activity through multiple mechanisms of action and it is approved with carfilzomib-dexamethasone or pomalidomide-dexamethasone for the treatment of patients (pts) with relapsed and/or refractory MM. A multi-center… read more here.
Keywords: noiint asct; isa vrd; asct pts; pts yrs ... See more keywords
Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-2267
Abstract: Introduction: In the phase 3 IMROZ study (NCT03319667), isatuximab (Isa) given intravenously (IV) with bortezomib, lenalidomide and dexamethasone (VRd) followed by Isa-Rd was associated with a significant progression-free survival (PFS) benefit in patients (pts) with… read more here.
Keywords: frail frail; non frail; isa vrd; pts yrs ... See more keywords
Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ study.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.7517
Abstract: 7517 Background: Gain or amplification of 1q21 (1q21+, ≥3 copies) is a chromosomal abnormality often detected in MM that can negatively affect prognosis by its involvement in resistance to therapy and MM progression. Results from… read more here.
Keywords: vrd; 1q21 status; isa vrd; vrd vrd ... See more keywords
Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial
Sign Up to like & getrecommendations! Published in 2025 at "Haematologica"
DOI: 10.3324/haematol.2024.287200
Abstract: Patients with multiple myeloma (MM) meeting frailty criteria have worse outcomes than those identified as non-frail. Here, we present a post hoc subgroup analysis of IMROZ, a global, phase III, open-label study investigating isatuximab (Isa)… read more here.
Keywords: isa vrd; subgroup analysis; analysis imroz; frail ... See more keywords